Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H Purged Non-myeloablative Allo-SCT
NCT00578942Phase 2Completed
- Start
- May 2005
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in lymphoma, multiple myeloma (MM), leukemia and 7 more. Primary endpoints: Toxicity at 1 year and Overall Survival at 12 years. Started May 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
lymphomamultiple myeloma (MM)leukemiamyelodysplastic syndrome (MDS)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00578942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578942.